SLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.

SLF1081851 hydrochloride is a potential inhibitor of Spns2 that blocks S1P release with an IC50 of 1.93 μM. It can be developed as a probe for studying Spns2 biology and immune modulation.

DDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.

DDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.

DDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.

DDO-2728 is a selective pyrazolopyrimidine-based inhibitor of ALKBH5 with an IC50 of 2.97 μM. It increases the levels of N6-methyladenosine (m6A) modifications in acute myeloid leukemia (AML) cells and exhibits antiproliferative activity in these cells. It also demonstrates anti-tumor efficacy in the MV4−11 xenograft model.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.

MZ-101 (GYS1-IN-2) is a potent small molecule inhibitor of Glycogen synthase 1(GYS1) with an IC50 value of 0.041 µM. By depleting muscle glycogen, MZ-101 treatment normalizes glycogen levels and corrects transcriptional and metabolic abnormalities in Pompe mice.